Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Use of bispecifics and CAR T cells in South America

Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA

Use of bispecifics and CAR T cells in South America ( Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA )

Tailored to fit: New approaches in transplant-ineligible NDMM

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Tailored to fit: New approaches in transplant-ineligible NDMM ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Advancements in minimal residual disease detection in myeloma

Dory Abelman, PhD Candidate - University of Toronto, Ontario, Canada

Advancements in minimal residual disease detection in myeloma ( Dory Abelman, PhD Candidate - University of Toronto, Ontario, Canada )

Novel biomarkers in myeloma: CTCs and cfDNA

Dr Bruno Paiva - Clinica Universidad de Navarra, Pamplona, Spain

Novel biomarkers in myeloma: CTCs and cfDNA ( Dr Bruno Paiva - Clinica Universidad de Navarra, Pamplona, Spain )

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new...

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Use of bispecifics and CAR T cells in South America

Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Use of bispecifics and CAR T cells in South America ( Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Revolutionising multiple myeloma treatment with CAR T-Cell therapies

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Revolutionising multiple myeloma treatment with CAR T-Cell therapies ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Gaza's cancer patients: Navigating the dual struggle of illness and war

Dr Ru'a Rimawi - Dana-Farber Cancer Institute, Boston, United States of America

Gaza's cancer patients: Navigating the dual struggle of illness and war ( Dr Ru'a Rimawi - Dana-Farber Cancer Institute, Boston, United States of America )

More from ecancer